FGFR-IN-10

FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs) . FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC50s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC50s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively[1].

Product Specifications

CAS Number

[2847092-41-3]

UNSPSC

12352005

Target

Cytochrome P450; FGFR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fgfr-in-10.html

Solubility

10 mM in DMSO

Smiles

FC(C=C1C2=CN=C(N=C2N3C[C@H](N([C@@H](C3)C)C(C=C)=O)C)NC4=CN(N=C4)C)=C(C=C1)OC5=NC=CC(C)=N5

Molecular Formula

C28H30FN9O2

Molecular Weight

543.60

References & Citations

[1]Zhu Wei, et al. Heterocyclic compound serving as FGFR inhibitor and application thereof: World Intellectual Property Organization, WO2022206939. 2022-10-06.